TY - JOUR
T1 - SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022 and 2023
AU - Lustig, Yaniv
AU - Canetti, Michal
AU - Indenbaum, Victoria
AU - Peretz, Yovel
AU - Weiss-Ottolenghi, Yael
AU - Margalit, Ili
AU - Asraf, Keren
AU - Levin, Tal
AU - Zuckerman, Neta
AU - Tomer, Enosh
AU - Mandelboim, Michal
AU - Doolman, Ram
AU - Barda, Noam
AU - Regev-Yochay, Gili
N1 - Publisher Copyright:
© 2024 Centers for Disease Control and Prevention (CDC). All rights reserved.
PY - 2024/5
Y1 - 2024/5
N2 - Although a vaccine against SARS-CoV-2 Omicron-XBB.1.5 variant is available worldwide and recent infection is protective, the lack of recorded infection data highlights the need to assess variant-specific antibody neutralization levels. We analyzed IgG levels against receptor-binding domain–specific SARS-CoV-2 ancestral strain as a correlate for high neutralizing titers against XBB variants.
AB - Although a vaccine against SARS-CoV-2 Omicron-XBB.1.5 variant is available worldwide and recent infection is protective, the lack of recorded infection data highlights the need to assess variant-specific antibody neutralization levels. We analyzed IgG levels against receptor-binding domain–specific SARS-CoV-2 ancestral strain as a correlate for high neutralizing titers against XBB variants.
UR - http://www.scopus.com/inward/record.url?scp=85191460821&partnerID=8YFLogxK
U2 - 10.3201/eid3005.231739
DO - 10.3201/eid3005.231739
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38666742
AN - SCOPUS:85191460821
SN - 1080-6040
VL - 30
SP - 1050
EP - 1052
JO - Emerging Infectious Diseases
JF - Emerging Infectious Diseases
IS - 5
ER -